Media headlines about Evolent Health (NYSE:EVH) have been trending positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evolent Health earned a media sentiment score of 0.42 on Accern’s scale. Accern also gave media coverage about the technology company an impact score of 46.4153871733488 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern’s rankings:
- Jefferies Group Comments on Evolent Health Inc’s FY2017 Earnings (EVH) (americanbankingnews.com)
- Jefferies Group Analysts Give Evolent Health (EVH) a $22.00 Price Target (americanbankingnews.com)
- Evolent Health, Inc. (EVH) Investors Checklist Stock – The Stocks News (press release) (thestocksnews.com)
- Were Analysts Bullish Evolent Health, Inc. (NYSE:EVH) This Week? – Reurope (reurope.com)
- Evolent Health, Inc. to Release Fourth Quarter and Full Year 2017 … – PR Newswire (press release) (prnewswire.com)
Several equities research analysts have commented on the stock. Jefferies Group set a $22.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird restated a “buy” rating and set a $25.00 target price on shares of Evolent Health in a research report on Wednesday, November 1st. Cantor Fitzgerald restated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Sunday, December 3rd. Goldman Sachs Group lowered shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. Finally, Citigroup assumed coverage on shares of Evolent Health in a research report on Thursday, January 4th. They set a “buy” rating on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the stock. Evolent Health has an average rating of “Buy” and an average target price of $27.40.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.